NORML’s Deputy Director Paul Armentano said: “These common-sense regulatory changes are necessary and long overdue. The reality that nearly one-half of US adults have legal access to these multitude of cannabis products, but our nation’s top scientists do not, is the height of absurdity and it is an indictment of the current system.”
Since 2010, scientists have published an estimated 27,000 peer-reviewed papers specific to cannabis, with the annual number of total papers increasing every year. NORML’s Deputy Director Paul Armentano said, “It is time for politicians and others to stop assessing cannabis through the lens of ‘what we don’t know’ and instead start engaging in evidence-based discussions about marijuana and marijuana reform policies that are indicative of all that we do know.”
“When it comes to addressing questions specific to the safety and therapeutic efficacy of cannabis, this publication provides the evidence that patients and their physicians – as well as lawmakers – need to know.”
This updated edition reviews over 450 peer-reviewed studies assessing the safety and efficacy of either whole-plant cannabis or cannabinoids for 23 different patient populations.
Researchers concluded, “We see no evidence that liberalized cannabis policies are directly associated with increased smoking behaviors among young adults.”
“The present study provides empirical evidence on the consequences of marijuana legalization on issues related to the labor market outcomes, in particular, WC [workers’ compensation] claiming of older adults. … Our findings suggest potentially important benefits to older workers and society at large.”
Since 2010, scientists have published over 23,000 peer-reviewed papers on cannabis, with the annual number of papers increasing every year.
For over five decades, federal regulators have only authorized a single licensee – the University of Mississippi – to cultivate cannabis plants for use in FDA-approved clinical studies.